Literature DB >> 9876375

Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470).

C N Qian1, H Q Min, H L Lin, M H Hong, Y L Ye.   

Abstract

OBJECTIVE: To evaluate the efficacy of the angiogenesis inhibitor AGM-1470 for the experimental treatment of nasopharyngeal carcinoma (NPC).
METHODS: A NPC human tumour model was built by tumour-bearing nude mice using the NPC cell line CNE-2. Twenty-one BALB/c nude mice bearing CNE-2 xenografts were randomized into a treatment group and a control group. In the treatment group, AGM-1470 was injected 30 mg/kg subcutaneously every other day; while the vehicle (three per cent ethanol solution in 0.9 per cent saline) was given to the mice in control group. Tumour volumes and animal weights were measured every third day. Autopsy was performed after 18 days of treatment. The tumour tissue as well as the murine tissues of heart, kidney, and liver in each mouse were removed for formalin fixation and routine HE staining. Pathological evaluation was performed in these tissues.
RESULTS: There was a significant difference in tumour volume between the two groups at day 9 of treatment and this increased thereafter. At day 15 of treatment, the tumour volume was 4251 +/- 559 mm3 (n = 10) in the control group versus 3122 +/- 967 mm3 (n = 11) in the AGM-1470 treated group (p = 0.004); and T:C ratio (mean tumour volume of treated/mean tumour volume of control) was 0.73, resulting in a 27 per cent decrease in tumour growth. Central necrosis and consequential shrinkage of tumours occurred in both groups at the end of experiment. Physical toxicity and histological toxicity of heart, liver, and kidney did not result from AGM-1470 therapy.
CONCLUSIONS: AGM-1470 suppresses the growth of the human NPC cell line CNE-2. Treatment by AGM-1470 has no physical nor histological toxicity. Angiogenesis inhibitors may be effective in the treatment of the local lesion of NPC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9876375     DOI: 10.1017/s0022215100141878

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  6 in total

1.  Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.

Authors:  Gregory K Hong; Pawan Kumar; Ling Wang; Blossom Damania; Margaret L Gulley; Henri-Jacques Delecluse; Peter J Polverini; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Angiogenesis inhibitor TNP-470 suppresses growth of peritoneal disseminating foci of human colon cancer line Lovo.

Authors:  Ying-Fang Fan; Zong-Hai Huang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

3.  Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Authors:  Edwin Pun Hui; Vivian W Y Lui; Cesar S C Wong; Brigette B Y Ma; Cecilia P Y Lau; Crystal S F Cheung; Kakiu Ho; Suk-Hang Cheng; Margaret H L Ng; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2010-05-15       Impact factor: 3.850

4.  Contrast-enhanced Ultrasound in evaluating of angiogenesis and tumor staging of nasopharyngeal carcinoma in nude mice.

Authors:  ShouJun Liang; Yong Gao; YaoLi Liu; ChengCheng Qiu; YanHao Chen; ShangYong Zhu
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

5.  Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma.

Authors:  Hui-Jie Zhang; Gao-Le Yuan; Qi-Lian Liang; Xiao-Xia Peng; Shao-Ang Cheng; Liang Jiang
Journal:  Oncol Lett       Date:  2018-03-16       Impact factor: 2.967

6.  Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.

Authors:  Qiuyan Chen; Linquan Tang; Na Liu; Feng Han; Ling Guo; Shanshan Guo; Jianwei Wang; Huai Liu; Yanfang Ye; Lu Zhang; Liting Liu; Pan Wang; Yingqin Li; Qingmei He; Xiaoqun Yang; Qingnan Tang; Yang Li; YuJing Liang; XueSong Sun; Chuanmiao Xie; Yunxian Mo; Ying Guo; Rui Sun; Haoyuan Mo; Kajia Cao; Xiang Guo; Musheng Zeng; Haiqiang Mai; Jun Ma
Journal:  Cancer Commun (Lond)       Date:  2018-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.